BRIDGES is a funding program designed to help translate lessons learned from clinical research, to benefit patients and communities around the globe by identifying special needs related to diabetes intervention and prevention. The initiative is also open to applicants in the Middle East.
Run by the International Diabetes Federation and supported by Eli Lilly, BRIDGES supports and funds experts to carry out innovative research into diabetes. The program has primarily been set up to encourage 'translational' research - a project to make the latest diabetes knowledge useful to everyday clinical and public health practices.
In the light of the growing diabetes epidemic in the region, translational research will help to improve prevention and will support evidence-based healthcare solutions in the field of diabetes.
"Lilly is a leader in diabetes care and is constantly developing new ways in which to create pioneering solutions for better patient care. With the prevalence of diabetes on the rise in the Middle East, BRIDGES will benefit patients in the region by identifying special needs that will aid the intervention and prevention of diabetes" said Rima Maalouf, Corporate Communication Manager, Middle East and North Africa, Eli Lilly and Company.
"We are encouraging the medical community in the Middle East Area to identify local projects and submit proposals to BRIDGES program"
According to the International Diabetes Federation, the GCC has some of the highest diabetes rates in the world; the UAE has the second highest percentage in the world with 20%. Saudi Arabia, Bahrain and Kuwait also have cause for concern, with 16.7%, 15.2% and 14.4% respectively of the population enduring the disease.
Despite these shocking figures, diabetes continues to be a growing pandemic and is the world's fourth leading cause of death by disease. It affects more than 240 million people worldwide and is expected to affect 380 million by 2025 .
"Although there have been tremendous advances in science, particularly through landmark clinical trials, diabetes still continues to rise, and the related morbidity and mortality have not been reduced. Translational research is needed to identify practical strategies that can improve the lives of people living with diabetes," said Professor Jean-Claude Mbanya, President-elect of IDF.
Browse
related articles
Eli Lilly supports International Diabetes Federation's BRIDGES program with a $10m research grant
- United Arab Emirates: Wednesday, October 17 - 2007 at 14:32
- PRESS RELEASE
Eli Lilly and Company (NYSE: LLY), the leading innovation-driven pharmaceutical corporation, announced its supports of the International Diabetes Federation (IDF) global BRIDGES (Bringing Research In Diabetes to Global Environments and Systems) program through a $10m research grant.
Related stories
Also consider reading:
Digg
Facebook
LinkedIn
Twitter
Browse
related articles
Log in to request more information from Lilly
Notes and media contacts
More information about BRIDGES:Through BRIDGES, the International Diabetes Federation, thanks to an educational grant from Eli Lilly, will provide funding for short term and long term projects over the course of seven years. Relevant topics include methods and strategies to improve health care delivery to people at risk of diabetes, enhancing diabetes self management and identifying people with undiagnosed diabetes in cost effective ways.
Grants are open for behavioral scientists, health services researchers, epidemiologists, economists, sociologists, psychologists, anthropologists, political scientists, medical informatics experts, biostatisticians, community experts, people living with diabetes, physicians, nurses, social workers, clinicians, nutritionists, physical activity experts and pharmacists.
The BRIDGES program is now open for applications and grant proposals. All grant proposals will be closely reviewed and prioritized by a cross-disciplinary external review group, managed by the International Diabetes Federation.
The application form is available at www.idfbridges.org. Grantees will be selected and announced in January 2008.
For further information, please contact Ronan L'Heveder, +32(0)2 5431634
Or Vivian Okonkwo, +32(0)25431631
About Lilly
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.
About IDF
The International Diabetes Federation (IDF) is the global advocate for the more than 240 million people with diabetes worldwide. It represents 200 diabetes associations in more than 160 countries. Its mission is to promote diabetes care, prevention and a cure worldwide. IDF is an NGO in official relations with the World Health Organization and an associated NGO with the United Nations Department of Public Information. Additional information about IDF is available at www.idf.org.
Issued by TBWA\RAAD, an exclusive Ketchum affiliate, on behalf of Eli Lilly (Suisse) S.A. For more information, kindly contact Maha Shoukri on telephone number +9714 2226667
Contact:
Maha Shoukri
TBWA\RAAD
Phone: (9714) 2226667 ext.234
Fax: (9714) 2226566
Posted by Lara Lynn Golden, News EditorWednesday, October 17 - 2007 at 14:32 UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of AME Info FZ LLC / Emap Limited.
Disclaimer:
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.
For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions
It looks like you are using a Mac - check out our 
Web Feeds